Compare Incyte Corporation (INCY) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs PepsiCo, Inc. — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while PepsiCo, Inc. trades at $135.3 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 8× Incyte Corporation's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PEP | |
|---|---|---|
Market Cap | $23.11B | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $170.44 |
52-Week Low | $67.38 | $135.40 |
Enterprise Value | $19.13B | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
PepsiCo (PEP) trades at $137.12, down 1.66% on the day, with technical indicators showing bearish momentum. The stock demonstrates strong fundamentals with consistent earnings beats, a 10.78% net income margin, and robust cash flow generation. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a predominantly hold rating with a $158.50 consensus price target representing 15.6% upside potential.
The outlook remains cautiously optimistic given PEP's stable dividend yield and operational resilience, though near-term headwinds include consumer price sensitivity and competitive pressures. The upcoming Q3 2026 earnings report on April 16 will be critical for validating the North American turnaround narrative and margin expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
